CDXS Codexis

Codexis to Present at Two Virtual Investment Conferences in September

Codexis to Present at Two Virtual Investment Conferences in September

REDWOOD CITY, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces that management will present at two upcoming virtual investment conferences:

  • H.C. Wainwright 22nd Annual Global Investment Conference on Monday, September 14, 2020 at 10:30 a.m. Eastern time (7:30 a.m. Pacific time).



  • Cantor Fitzgerald Virtual Global Healthcare Conference in a fireside chat format on Thursday, September 17, 2020 at 8:00 a.m. Eastern time (5:00 a.m. Pacific time).

A live webcast and replay of the presentations will be available on the Investors section of the company’s website, .

About Codexis, Inc.

Codexis is a leading protein engineering company that applies its proprietary CodeEvolver® technology to develop proteins for a variety of applications, including as biocatalysts for the commercial manufacture of pharmaceuticals, fine chemicals and industrial enzymes, and enzymes as biotherapeutics and for use in molecular diagnostics. Codexis’ proven technology enables improvements in protein performance, meeting customer needs for rapid, cost-effective and sustainable manufacturing in multiple commercial-scale implementations of biocatalytic processes. For more information, see .

Contact: 

LHA Investor Relations

Jody Cain, 310-691-7100

EN
08/09/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Codexis

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: December 1, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Codexis Announces Signing of Lease for GMP Manufacturing Facility

Codexis Announces Signing of Lease for GMP Manufacturing Facility REDWOOD CITY, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, today announced that it has signed a lease for a 34,000 square foot GMP manufacturing facility in Hayward, California. The multi-purpose facility will allow Codexis to expand its internal capabilities into GMP manufacturing of siRNA and other oligonucleotides using its ECO Synthesis platform. The company expects to begin modific...

 PRESS RELEASE

Codexis Reports Third Quarter 2025 Financial Results

Codexis Reports Third Quarter 2025 Financial Results Announces signing of $37.8m Supply Assurance Agreement with Merck Organizational changes streamline company and reduce operational expenses Cash runway extended through 2027 REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, today announced financial results for the third quarter ended September 30, 2025. The company also provided a business update that includes signing a $37.8m Supply Ass...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch